Overdue and Lost to Follow-Up as Distinct States: Operational Implications for the Medical Outcomes Audit, Tracking Architecture, and Closed-Loop Navigation

Overdue for follow-up and lost to follow-up represent two distinct operational states along the breast-imaging pathway. Keeping them separate allows a practice to see which patients remain reachable and actionable, and which patients have moved beyond current intervention capacity. This distinction strengthens the integrity of the mammography medical outcomes audit required under the Mammography Quality Standards Act (MQSA), supports accurate tracking, and clarifies whether navigation records stay open or become permanently unresolved.

Two Distinct States in the Diagnostic Pathway

Under MQSA, every mammography report must carry one of the Food and Drug Administration (FDA) assessment categories. These include the final assessments Negative, Benign, Probably Benign, Suspicious, Highly Suggestive of Malignancy, Known Biopsy-Proven Malignancy, and Post-Procedure Mammogram for Marker Placement, as well as the incomplete assessments "Incomplete: Need additional imaging evaluation" and "Incomplete: Need prior mammograms for comparison."¹ Many facilities additionally elect to use the American College of Radiology Breast Imaging Reporting and Data System® (BI-RADS®) lexicon, which maps numeric categories onto the same FDA taxonomy and supplies standardized management recommendations.²

A patient becomes overdue for follow-up when the interpreting physician has issued a recommendation that requires action -- additional imaging after an incomplete assessment, short-interval surveillance after a Probably Benign finding, or tissue sampling after a Suspicious or Highly Suggestive of Malignancy assessment -- and the recommended interval has passed without completion, yet the case remains active in the tracking system. Validated electronic triggers in large electronic-health-record cohorts flag these delays at practical thresholds of more than 60 days for incomplete, Suspicious, or Highly Suggestive assessments and more than 7 months for Probably Benign assessments.³ At this stage the recommendation is still known, contact information is presumed current, and outreach can still convert the status to completed.

Lost to follow-up is the later state in which the recommended action has not occurred after the overdue window, documented outreach attempts have failed to produce resolution, or the patient is no longer reachable within the health system after a longer defined period. Systematic reviews of follow-up after abnormal mammography document that investigators operationalize this state in several ways: failure to attend a scheduled appointment, failure to complete any follow-up within a fixed interval such as 3 or 6 months, or failure to reach diagnostic resolution.⁴ Rates of non-attendance within 3 months range from 7.2 percent to 33 percent across studies; rates at 6 months range from 27.3 percent to 71.6 percent. Observational work further suggests that the most common patient-level reasons include lack of time and the perception that personal health is already good.⁵

The operational difference is therefore temporal and systemic. Overdue remains a reversible, system-visible status that still permits intervention. Lost to follow-up is the status that remains after intervention capacity is exhausted or abandoned. Practices that keep these two statuses distinct can measure the conversion rate from overdue to completed and can identify the residual volume of unresolved cases that enter the annual audit as data gaps.

How the Distinction Shapes the Medical Outcomes Audit

MQSA requires every certified facility to establish and maintain a system that collects and reviews outcome data for all mammograms, including follow-up on the disposition of all positive mammograms and correlation of pathology results with the interpreting physician's findings. Analysis must be performed both individually for each interpreting physician and collectively for the facility. Amended regulations effective September 2024 further require calculation of three specific metrics: positive predictive value, cancer detection rate, and recall rate.¹

Patients who remain overdue or progress to lost to follow-up affect these calculations directly. Incomplete ascertainment of imaging or pathology outcomes underestimates cancer detection rate and distorts positive predictive value because the denominator of positive assessments includes cases whose true status is unknown. Simulation studies demonstrate that lower rates of pathology ascertainment increase the probability that a facility or individual radiologist will fall below established performance benchmarks for cancer detection rate.⁶ ACR guidance further notes that meaningful screening audits treat incomplete assessments as positive; failure to track their resolution therefore systematically undercounts the true abnormal interpretation rate and the subsequent diagnostic yield.² Facilities that cannot separate overdue from lost to follow-up cannot quantify how many of their positive assessments remain open versus permanently unresolved, leaving the audit incomplete by construction.

Tracking Architecture and the Conversion Opportunity

Effective tracking systems surface the overdue cohort in real time so that outreach can occur while contact remains feasible. Electronic triggers that flag delays at the 60-day and 7-month thresholds have demonstrated positive predictive values around 71 percent when applied to large cohorts, identifying hundreds of true delays among thousands of abnormal examinations.³ Once flagged, the system documents each outreach attempt, the outcome of that attempt, and the final disposition. Practices that maintain this layered status architecture can calculate three independent rates: the proportion of positive assessments that become overdue, the conversion rate from overdue to completed, and the residual lost-to-follow-up rate after outreach. These rates feed directly into the MQSA audit and allow targeted allocation of navigator effort.

Closed-Loop Versus Open-Loop Navigation Records

Patient navigation interventions increase both screening uptake and follow-up after abnormal results. A recent systematic review and meta-analysis of randomized trials reported a risk ratio of 1.23 for completion of follow-up after abnormal mammography among women offered navigation compared with usual care.⁷ The mechanism is closed-loop documentation: the recommendation is identified, the patient and referring clinician are notified, completion is confirmed, and the outcome is recorded so the loop is formally closed. Open-loop records stop at the recommendation itself. In the absence of systematic tracking to resolution, the same recommendation that appears complete on the radiology report remains unresolved in the patient's longitudinal record.

Closed-loop imaging programs that index radiology reports containing follow-up recommendations, assign nurse coordinators to chart review and outreach, and document resolution have increased adherence rates for actionable findings and reduced the volume of unresolved cases.⁸ These programs treat overdue status as the trigger for active intervention and reserve lost-to-follow-up status for cases that remain unresolved after defined outreach protocols (typically multiple telephone attempts followed by written notification). Open-loop environments lack this escalation path; the recommendation is issued and the case simply ages into permanent non-resolution.

Patient Consequence and Operational Implication

Longer intervals between an abnormal screening result and diagnostic resolution are associated with higher odds of larger tumor size and lymph-node involvement once cancer is diagnosed. The Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Consortium systematic review concludes that risk for poorer cancer outcomes rises with prolonged wait times, supporting diagnostic testing as soon as feasible after a positive result, while acknowledging that evidence quality remains limited by confounding.⁹ Every case that transitions from overdue to lost to follow-up therefore represents a measurable erosion of the mortality benefit that screening is intended to deliver.

Practices that maintain separate, time-stamped statuses for overdue and lost to follow-up gain a practical set of process metrics that map directly onto the MQSA audit requirements, support focused navigator effort, and generate the documentation needed to demonstrate that the facility has fulfilled its obligation to track disposition of positive examinations. Facilities that collapse the two states into a single "incomplete" category cannot isolate the intervenable population and therefore cannot improve the conversion rate that actually determines patient outcome.

Leadership Question

If the tracking system cannot yet distinguish a patient who is still reachable and overdue from a patient whose diagnostic loop has already failed, what single process change would most improve the volume of unresolved positive examinations that enter the next annual audit as permanent data gaps?

---

About the Author

Richard D. Lippert Jr. is the founder of Mammologix and has supported breast imaging centers with patient follow-up tracking, lay communication, compliance documentation, and operational strategy since 1995.

References

1. US Food and Drug Administration. Mammography Quality Standards Act regulations, 21 CFR 900.12(c) and (f). Amended requirements effective September 10, 2024. fda.gov/mqsa-and-program

2. American College of Radiology. ACR BI-RADS® Atlas, 5th ed. Reston, VA: American College of Radiology; 2013 (with subsequent updates). acr.org/BI-RADS

3. Murphy DR, et al. Electronic triggers to identify delays in follow-up of mammography: harnessing the power of big data in health care. J Am Coll Radiol. 2018;15(2):287-295. doi:10.1016/j.jacr.2017.10.001. Abstract

4. Houssami N, et al. Delayed or failure to follow-up abnormal breast cancer screening mammograms in primary care: a systematic review. BMC Cancer. 2021;21:373. doi:10.1186/s12885-021-08100-3. bmccancer.biomedcentral.com

5. Kuo CS, et al. Women with abnormal screening mammography lost to follow-up: an experience from Taiwan. Medicine (Baltimore). 2016;95(24):e3889. doi:10.1097/MD.0000000000003889. journals.lww.com

6. Sprague BL, et al. The importance of outcomes ascertainment for accurate assessment of the mammography screening cancer detection rate: a simulation study. J Am Coll Radiol. 2024;21(2). doi:10.1016/j.jacr.2023.08.045

7. Nelson HD, et al. Patient navigation services for breast and cervical cancer screening and follow-up: a meta-analysis. JAMA Intern Med. 2025. doi:10.1001/jamainternmed.2025. jamanetwork.com

8. Aripoli A, et al. The impact of closed-loop imaging on actionable CT-detected breast findings. J Am Coll Radiol. 2024;21(7):1024-1032. doi:10.1016/j.jacr.2024.01.006. Full text

9. Doubeni CA, et al. Timely follow-up of positive cancer screening results: a systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin. 2018;68(3):199-216. doi:10.3322/caac.21452. doi:10.3322/caac.21452